Summary of Awards
1) The ISV Presidential Travel awards for trainees (graduate students and post-doctoral trainees who submit abstracts), which is funded generously by Dr. Margaret Liu, ISV President. Ten $500 awards will be offered to reimburse attendance costs based upon the evaluation of the abstracts by the scientific committee. When trainees submit their abstract and register for the Congress via the Congress website, they will be able to indicate their interest in applying for one of these awards, and will also need to provide a letter from their lab head indicating their trainee status.
2) ISV anticipates being able to provide funding to assist some attendees coming from Lower and Middle Income Countries to present their science at the Congress. Scientists desiring to be considered for one of these awards need to specify their interest after their submission of the required abstract. Decisions will be made based on evaluation of the submitted abstract by the scientific committee and amount of funds available.
3) Maurice Hilleman Award
This award is given annually to the lead author of the outstanding submitted abstract of the ISV Vaccines Congress. It serves to recognize our colleague, friend and mentor Dr. Maurice Hilleman. Dr. Hilleman was simply the person who developed more vaccines (40) than any other person. 8 of the 14 recommended vaccines currently given to children including measles, mumps, hepatitis A, HBV, chickenpox, meningitis, pneumonia and haemophilus influenzae bacteria were all developed under his guidance. His pioneering work on development of a recombinant HBV vaccine helped to show the importance of the growing field of biotechnology. He played a major role in the discovery of adenoviruses and hepatitis viruses and SV40. It is without question that the work of Maurice has changed the human condition for the better resulting in millions of lives saved and countless suffering averted yearly. Dr. Hilleman was a staunch proponent of the DNA technology and one of our fields greatest supporters. We are proud to honor his legacy through providing this award to a worthy scientist for their exceptional work each year.
4) Richard Ginsberg Award
This award is given annually to the best abstract submission by a trainee at the ISV Vaccines Congress. It serves to recognize and honor our colleague and friend, Dr. Richard Ginsberg. “Richard” was a major proponent of the DNA vaccine field as well as a proponent for developing new treatments and vaccine technologies for treatment of diseases afflicting the underserved as well as developing world populations. As a clinical director at Roche Pharmaceuticals in the 1980’s and 1990’s he oversaw development of one of the world’s first protease inhibitors for HIV, thus making a major contribution to converting this disease from a death sentence to a treatable condition. His role as CMO at Apollon and later Wyeth in the 1990’s he used to successfully champion the first DNA vaccines into the clinic which establish an unprecedented level of safety for this important platform. Richards inclusive nature and delight in his colleagues also served to establish a great deal of the camaraderie with in the community that still is of major benefit for researchers in the field. We are proud to honor his legacy and to honor a worthy young scientist each year with this award.
5) Vaccine Renaissance Scholarship for Women and Minority Delegates
The organizers of Vaccine Renaissance have traditionally provided funding to women or under-represented minority delegates to attend its conferences. This year, Vaccine Renaissance XI will occur in conjunction with the 2017 ISV Annual Congress in Paris, France, and will continue to offer the same scholarship opportunities. This fund will provide travel awards for selected delegates to attend this year’s conference in Paris.
In order to qualify, you must be a young woman or a young, under-represented minority working in the field of vaccine research and development. Candidates in pre-doctoral, doctoral, post-doctoral and assistant professor positions are eligible to apply.
Funding for this conference is made possible [in part] by 5 R13 AI 094946 -07 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessary reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.